BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

595 related articles for article (PubMed ID: 24508063)

  • 1. Honokiol inhibits epithelial-mesenchymal transition in breast cancer cells by targeting signal transducer and activator of transcription 3/Zeb1/E-cadherin axis.
    Avtanski DB; Nagalingam A; Bonner MY; Arbiser JL; Saxena NK; Sharma D
    Mol Oncol; 2014 May; 8(3):565-80. PubMed ID: 24508063
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Honokiol inhibits breast cancer cell metastasis by blocking EMT through modulation of Snail/Slug protein translation.
    Wang WD; Shang Y; Li Y; Chen SZ
    Acta Pharmacol Sin; 2019 Sep; 40(9):1219-1227. PubMed ID: 31235819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Honokiol activates LKB1-miR-34a axis and antagonizes the oncogenic actions of leptin in breast cancer.
    Avtanski DB; Nagalingam A; Bonner MY; Arbiser JL; Saxena NK; Sharma D
    Oncotarget; 2015 Oct; 6(30):29947-62. PubMed ID: 26359358
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Roles of STAT3 and ZEB1 proteins in E-cadherin down-regulation and human colorectal cancer epithelial-mesenchymal transition.
    Xiong H; Hong J; Du W; Lin YW; Ren LL; Wang YC; Su WY; Wang JL; Cui Y; Wang ZH; Fang JY
    J Biol Chem; 2012 Feb; 287(8):5819-32. PubMed ID: 22205702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Honokiol abrogates leptin-induced tumor progression by inhibiting Wnt1-MTA1-β-catenin signaling axis in a microRNA-34a dependent manner.
    Avtanski DB; Nagalingam A; Kuppusamy P; Bonner MY; Arbiser JL; Saxena NK; Sharma D
    Oncotarget; 2015 Jun; 6(18):16396-410. PubMed ID: 26036628
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Honokiol Inhibits Constitutive and Inducible STAT3 Signaling via PU.1-Induced SHP1 Expression in Acute Myeloid Leukemia Cells.
    Bi L; Yu Z; Wu J; Yu K; Hong G; Lu Z; Gao S
    Tohoku J Exp Med; 2015 Nov; 237(3):163-72. PubMed ID: 26466521
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Honokiol inhibits EMT-mediated motility and migration of human non-small cell lung cancer cells in vitro by targeting c-FLIP.
    Lv XQ; Qiao XR; Su L; Chen SZ
    Acta Pharmacol Sin; 2016 Dec; 37(12):1574-1586. PubMed ID: 27593221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Honokiol Decreases Lung Cancer Metastasis through Inhibition of the STAT3 Signaling Pathway.
    Pan J; Lee Y; Zhang Q; Xiong D; Wan TC; Wang Y; You M
    Cancer Prev Res (Phila); 2017 Feb; 10(2):133-141. PubMed ID: 27849557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fra-1/AP-1 induces EMT in mammary epithelial cells by modulating Zeb1/2 and TGFβ expression.
    Bakiri L; Macho-Maschler S; Custic I; Niemiec J; Guío-Carrión A; Hasenfuss SC; Eger A; Müller M; Beug H; Wagner EF
    Cell Death Differ; 2015 Feb; 22(2):336-50. PubMed ID: 25301070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BCL6 induces EMT by promoting the ZEB1-mediated transcription repression of E-cadherin in breast cancer cells.
    Yu JM; Sun W; Hua F; Xie J; Lin H; Zhou DD; Hu ZW
    Cancer Lett; 2015 Sep; 365(2):190-200. PubMed ID: 26049022
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Honokiol: A polyphenol neolignan ameliorates pulmonary fibrosis by inhibiting TGF-β/Smad signaling, matrix proteins and IL-6/CD44/STAT3 axis both in vitro and in vivo.
    Pulivendala G; Bale S; Godugu C
    Toxicol Appl Pharmacol; 2020 Mar; 391():114913. PubMed ID: 32032644
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activation of tumor suppressor LKB1 by honokiol abrogates cancer stem-like phenotype in breast cancer via inhibition of oncogenic Stat3.
    Sengupta S; Nagalingam A; Muniraj N; Bonner MY; Mistriotis P; Afthinos A; Kuppusamy P; Lanoue D; Cho S; Korangath P; Shriver M; Begum A; Merino VF; Huang CY; Arbiser JL; Matsui W; Győrffy B; Konstantopoulos K; Sukumar S; Marignani PA; Saxena NK; Sharma D
    Oncogene; 2017 Oct; 36(41):5709-5721. PubMed ID: 28581518
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stat3-coordinated Lin-28-let-7-HMGA2 and miR-200-ZEB1 circuits initiate and maintain oncostatin M-driven epithelial-mesenchymal transition.
    Guo L; Chen C; Shi M; Wang F; Chen X; Diao D; Hu M; Yu M; Qian L; Guo N
    Oncogene; 2013 Nov; 32(45):5272-82. PubMed ID: 23318420
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Honokiol suppresses renal cancer cells' metastasis via dual-blocking epithelial-mesenchymal transition and cancer stem cell properties through modulating miR-141/ZEB2 signaling.
    Li W; Wang Q; Su Q; Ma D; An C; Ma L; Liang H
    Mol Cells; 2014 May; 37(5):383-8. PubMed ID: 24810210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Loss of the polycomb protein Mel-18 enhances the epithelial-mesenchymal transition by ZEB1 and ZEB2 expression through the downregulation of miR-205 in breast cancer.
    Lee JY; Park MK; Park JH; Lee HJ; Shin DH; Kang Y; Lee CH; Kong G
    Oncogene; 2014 Mar; 33(10):1325-35. PubMed ID: 23474752
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metformin reverses mesenchymal phenotype of primary breast cancer cells through STAT3/NF-κB pathways.
    Esparza-López J; Alvarado-Muñoz JF; Escobar-Arriaga E; Ulloa-Aguirre A; de Jesús Ibarra-Sánchez M
    BMC Cancer; 2019 Jul; 19(1):728. PubMed ID: 31337349
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Src promotes EGF-induced epithelial-to-mesenchymal transition and migration in gastric cancer cells by upregulating ZEB1 and ZEB2 through AKT.
    Zhao L; Li X; Song N; Li A; Hou K; Qu X; Che X; Liu Y
    Cell Biol Int; 2018 Mar; 42(3):294-302. PubMed ID: 29052277
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIF-1α Promotes Epithelial-Mesenchymal Transition and Metastasis through Direct Regulation of ZEB1 in Colorectal Cancer.
    Zhang W; Shi X; Peng Y; Wu M; Zhang P; Xie R; Wu Y; Yan Q; Liu S; Wang J
    PLoS One; 2015; 10(6):e0129603. PubMed ID: 26057751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An hTERT/ZEB1 complex directly regulates E-cadherin to promote epithelial-to-mesenchymal transition (EMT) in colorectal cancer.
    Qin Y; Tang B; Hu CJ; Xiao YF; Xie R; Yong X; Wu YY; Dong H; Yang SM
    Oncotarget; 2016 Jan; 7(1):351-61. PubMed ID: 26540342
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CCN6 (WISP3) decreases ZEB1-mediated EMT and invasion by attenuation of IGF-1 receptor signaling in breast cancer.
    Lorenzatti G; Huang W; Pal A; Cabanillas AM; Kleer CG
    J Cell Sci; 2011 May; 124(Pt 10):1752-8. PubMed ID: 21525039
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.